Age-Related Macular Degeneration | Current Treatment | EU5 | 2016
Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued strong uptake of Eylea in Europe threatens Lucentis’s historical position as the patient-share leader in this market, while use of off-label Avastin differs across the EU5 countries. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Dry and Wet Age-Related Macular Degeneration Current Treatment EU offers a snapshot of how EU5 ophthalmologists are currently managing their dry and wet AMD patients, with a particular focus on the use of anti-VEGF for wet AMD, as well as insight into the factors driving such prescribing habits.
